Prevalence of iron overload vs iron deficiency in multiple myeloma: Resembling or different from MDS - And stem cell transplant (SCT) - Patients?

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 6, 2013, Pages 671-

  König, Christine ^a   Kleber, Martina ^a   Ihorst, Gabriele ^b   Gropp, Anette ^b   Reinhardt, Heike ^a   Koch, Bernd ^b   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anemia; Multiple myeloma patients; Normal iron metabolism; Outcome; Risk factors

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BORTEZOMIB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; FERRITIN; IFOSFAMIDE; IRON; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; TRANSFERRIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

ANEMIA; MULTIPLE MYELOMA PATIENTS; NORMAL IRON METABOLISM; OUTCOME; RISK FACTORS;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON; IRON OVERLOAD; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; PREVALENCE;

EID: 84887989854     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.06.001     Document Type: Article

References (33)

1. K. Maes, E. Nemeth, and G.D. Roodman In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2 Blood 116 2010 3635 3644
2. R.A. Kyle, and S.V. Rajkumar Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 2009 3 9
3. A. Cucuianu, M. Patiu, and A. Rusu Hepcidin and multiple myeloma related anemia Med Hypotheses 66 2006 352 354
4. R.A. Kyle, M.A. Gertz, and T.E. Witzig Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 2003 21 33
5. Z.N. Ozkurt, Z.A. Yegin, and E. Suyani Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation J Clin Apher 25 2010 280 286
6. P. Armand, H.T. Kim, and C.S. Cutler Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation Blood 109 2007 4586 4588
7. A. Mahindra, B. Bolwell, and R. Sobecks Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma Biol Blood Marrow Transplant 14 2008 1239 1244
8. A. Mahindra, R. Sobecks, and L. Rybicki Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation Bone Marrow Transplant 44 2009 767 768
9. A. Mahindra, B. Bolwell, and R. Sobecks Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation Br J Haematol 146 2009 310 316
10. A. Altes, A.F. Remacha, and P. Sarda Early clinical impact of iron overload in stem cell transplantation. A prospective study Ann Hematol 86 2007 443 447
11. G.T. Sucak, Z.A. Yegin, and Z.N. Ozkurt The role of liver biopsy in the workup of liver dysfunction late after SCT: is the role of iron overload underestimated? Bone Marrow Transplant 42 2008 461 467
12. M.H. Miceli, L. Dong, and M.L. Grazziutti Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients Bone Marrow Transplant 37 2006 857 864
13. V. Pullarkat Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114 2009 5251 5255
14. P. Brissot, M. Ropert, and C. Le Lan Non-transferrin bound iron: a key role in iron overload and iron toxicity Biochim Biophys Acta 1820 2012 403 410
15. R.J. Pessoa-Magalhaes, M.B. Vidriales, and B. Paiva Analysis of the immune system of multiple myeloma patients achieving long-term disease control, by multidimensional flow cytometry Haematologica 98 2013 79 86
16. A. Markert, V. Thierry, and M. Kleber Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment Int J Cancer 124 2009 722 728
17. M. Engelhardt, G. Ihorst, and J. Udi Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness? A systemic approach by detailed analysis via the electronic tumor base documentation system Onkologie 34 2011 688 694
18. M. Kleber, M. Cybulla, and K. Bauchmuller Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice Ann Oncol 18 2007 950 958
19. M. Kleber, G. Ihorst, and B. Deschler Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients Eur J Haematol 83 2009 519 527
20. M. Kleber, G. Ihorst, and M. Terhorst Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score Blood Cancer J 1 2011 e35
21. H. Ludwig, G. Endler, and B. Klement High prevalence of iron deficiency in patients with various hematological and malignant diseases: a single center study in 1989 sequential patients Haematologica 95 suppl 2010 abstract 703
22. P. Przybylowski, J. Malyszko, and J.S. Malyszko Anemia in heart and kidney allograft recipients: is there a role for hepcidin? Transplant Proc 42 2010 4255 4258
23. P. Przybylowski, J. Malyszko, and I. Glowinska Prevalence of iron deficiency in heart and kidney allograft recipients Transplant Proc 43 2011 3885 3887
24. S. Reinke, W.R. Taylor, and G.N. Duda Absolute and functional iron deficiency in professional athletes during training and recovery Int J Cardiol 156 2012 186 191
25. P.S. Haas, K. Bauchmuller, and A. Kuhnemund Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period Ann Hematol 85 2006 191 193
26. M. Kleber, J. Udi, and B. Metzke Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy Leuk Lymphoma 53 2012 1057 1061
27. Steinmetz Tilman RR, Weber-Mangal S, Tesch H, et al. A prospective observational review of ferric carboymaltose alone in the improvement of anemia secondary to iron deficiency in cancer patients. 15th European Hematology Association, 2010 Barcelona, Spain. Abstract 1911.
28. S.D. Anker, J. Comin Colet, and G. Filippatos Ferric carboxymaltose in patients with heart failure and iron deficiency New Engl J Med 361 2009 2436 2448
29. P.A. Krayenbuehl, E. Battegay, and C. Breymann Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration Blood 118 2011 3222 3227
30. S.C. Maradei, A. Maiolino, and A.M. de Azevedo Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation Blood 114 2009 1270 1275
31. G.T. Sucak, Z.N. Ozkurt, and Z. Aki Cardiac systolic function in patients receiving hematopoetic stem cell transplantation: risk factors for posttransplantation cardiac toxicity Transplant Proc 40 2008 1586 1590
32. M.K. Song, J.S. Chung, and Y.M. Seol Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma Korean J Int Med 24 2009 368 373
33. P. Fenaux, and C. Rose Impact of iron overload in myelodysplastic syndromes Blood Rev 23 suppl 1 2009 S15 S19